We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Manufacturing Violations Lead to Consent Decree for OTC Drugmaker
Manufacturing Violations Lead to Consent Decree for OTC Drugmaker
November 29, 2005
OTC drugmaker Molecular Biologics (MBI) has signed a consent decree with the FDA requiring it to cease manufacturing and distributing its drug products until it can resolve repeated manufacturing violations at its Benicia, Calif., plant.